La Jolla Pharmaceutical Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/12/2022)
| Balance Sheet | Total Assets | 101,230,000.00 | ROE | – |
| Balance Sheet | Total Equity | -66,738,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -9,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 28,235,000.00 | – | – |
| Cashflow | Operating Cash Flow | 28,244,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 0.58 | Div. Yield | – |
| Income | Net Income | 19,660,000.00 | P/E | – |
| Income | Shares Outstanding | 27,497,000.00 | P/B | – |
| Income | Total Revenue | 75,720,000.00 | P/S | – |
Ratios calculated on: –
Company Description
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.lajollapharmaceutical.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more